Apollomics Reports Vebreltinib Data At The 2024 ASCO Annual Meeting

6/4/24 8:23:32 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $APLM alert in real time by email

Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced a poster presentation and an oral presentation by partner company, Avistone Biotechnology, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31-June 4, 2024, in Chicago, Ill. and virtually. Copies of the poster and oral presentation are available on the Apollomics website at ir.apollomicsinc.com/news-events/presentations.

Get the next $APLM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APLM

Date	Price Target	Rating	Analyst

More analyst ratings

$APLM
Press Releases

Fastest customizable press release news feed in the world

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. The Phase 3 trial was a randomized, double-blinded bridging trial to evaluate the safety and efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with relapsed or refract
12/20/24 8:00:00 AM ET
$APLM
Biotechnology: Pharmaceutical Preparations
Health Care
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) (the "Bid Price Requirement"), and Nasdaq has determined to continue the listing of the Company's Class A ordinary shares ("Class A Ordinary Shares") on the Nasdaq Capital Market under the symbo
12/10/24 4:05:00 PM ET
$APLM
Biotechnology: Pharmaceutical Preparations
Health Care
Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
FOSTER CITY, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it will affect a 1-for-100 reverse share split ("Reverse Share Split") of its class A ordinary shares, par value $0.0001 per share ("Old Shares"), which will become effective at 12:01a.m. Eastern Time on Monday, November 25, 2024 (the "Effective Time"). The Company's new class A ordinary shares, par value $0.01 per share ("New Shares") will begin trading on a split-adjusted basis on the Nasdaq Stock
11/21/24 8:00:00 AM ET
$APLM
Biotechnology: Pharmaceutical Preparations
Health Care

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-
3/28/24 7:00:00 AM ET
$APLM
Biotechnology: Pharmaceutical Preparations
Health Care
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co
3/26/24 8:00:00 AM ET
$APLM
Biotechnology: Pharmaceutical Preparations
Health Care
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou
9/28/23 4:17:57 PM ET
$APLM
Biotechnology: Pharmaceutical Preparations
Health Care

Apollomics Reports Vebreltinib Data At The 2024 ASCO Annual Meeting

Chat with this insight

Recent Analyst Ratings for
$APLM

$APLM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

$APLM
Press Releases

Fastest customizable press release news feed in the world

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

$APLM
SEC Filings

$APLM
Financials

Live finance-specific insights

SEC Form 6-K filed by Apollomics Inc.

SEC Form 6-K filed by Apollomics Inc.

SEC Form 6-K filed by Apollomics Inc.

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Apollomics Reports Vebreltinib Data At The 2024 ASCO Annual Meeting

Chat with this insight

Recent Analyst Ratings for $APLM

$APLM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

$APLM Press Releases

Fastest customizable press release news feed in the world

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

$APLM SEC Filings

$APLM Financials

Live finance-specific insights

SEC Form 6-K filed by Apollomics Inc.

SEC Form 6-K filed by Apollomics Inc.

SEC Form 6-K filed by Apollomics Inc.

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Recent Analyst Ratings for
$APLM

$APLM
Large Ownership Changes

$APLM
Press Releases

$APLM
SEC Filings

$APLM
Financials